News FDA clears subcutaneous Keytruda in a boost to MSD MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.
Oncology Current and future standard of care in prostate cancer Despite recent advancements in the field of prostate cancer treatment, there remain distinct gaps in the current standard of care needing improvement.
News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
Oncology Sponsored 12 Questions with Rick Coope Rick Coope is General Manager at Menarini Stemline UK, Ireland, and the Nordics.
News J&J claims FDA okay for bladder cancer drug TAR-200 Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.